The estimate begins with the treatment strategy, not the diagnosis label
Two patients with the same diagnosis can have very different costs. A small stable residual tumor under surveillance differs from a first operation for optic-chiasm compression, a recurrent tumor after radiotherapy or a BRAF-mutant papillary tumor being considered for molecular therapy.
MRI, vision and endocrine work-up are core planning costs
A specialist review may require current sellar/suprasellar MRI, formal visual-field testing and a comprehensive pituitary hormone assessment. Additional endocrine testing can be needed when adrenal, thyroid, gonadal, growth-hormone or water-balance function is unclear.
Surgical route and anatomical complexity drive the operative estimate
Endoscopic endonasal surgery and transcranial surgery use different teams, operating-room resources and reconstruction needs. Large cystic tumors, ventricular extension, vascular adherence, prior operations or hypothalamic involvement can change operative time and inpatient monitoring.
CSF leak and hydrocephalus can materially change resource use
Skull-base surgery can require multilayer reconstruction and postoperative CSF-leak surveillance. Some patients also need temporary or permanent CSF diversion for hydrocephalus. These are not appropriate to assume in every quote, but they can substantially change the final bill when clinically necessary.
Endocrine replacement and sodium/water monitoring belong in the episode
Craniopharyngioma surgery can alter cortisol, thyroid, gonadal and antidiuretic-hormone function. Postoperative endocrine monitoring and treatment of diabetes insipidus or other pituitary deficits can affect length of stay and follow-up requirements.
Radiotherapy is a separate major cost driver
Planned radiotherapy after subtotal resection or treatment of growing residual/recurrent disease involves simulation, dosimetry, repeated treatment sessions and specialist follow-up. Previous radiation changes the planning problem and can make re-irradiation a separate high-complexity evaluation.
Papillary BRAF V600E review can add molecular and drug-treatment costs
For selected adult papillary craniopharyngiomas, pathology confirmation and BRAF V600E testing can open a BRAF/MEK-inhibitor discussion. This is not a universal standard package and drug access, regimen, monitoring and regulatory status must be clarified by the treating center. Molecular therapy can therefore represent a separate cost pathway rather than an assumed component of every craniopharyngioma estimate.
Recurrent disease requires previous treatment records before quoting
A realistic estimate after recurrence depends on prior operative approach, residual anatomy, pathology, radiotherapy dose and field, endocrine status and current vision. Reoperation, radiotherapy/re-irradiation or targeted-therapy review cannot be priced meaningfully from the diagnosis name alone.
Long-term endocrine and rehabilitation costs extend beyond the procedure
Some patients need lifelong hormone replacement, metabolic management, visual follow-up, neuropsychological support or rehabilitation for hypothalamic and cognitive effects. These ongoing costs may fall outside an initial hospital treatment estimate and should be planned separately.
German international-patient estimates follow record review
Heidelberg states that once required DICOM imaging and reports are complete, specialists review the case, decide whether treatment can be offered and then generate a treatment offer with the corresponding cost calculation. Charité International likewise reviews international requests with clinical teams and can prepare an expected-stay estimate for accepted inpatient treatment.
Send these records before requesting a quote
A complete packet reduces back-and-forth and helps the hospital define the correct treatment episode.
- Current and previous sellar/suprasellar MRI DICOM files
- Radiology reports
- Visual-field and visual-acuity reports
- Current endocrine labs and hormone-replacement list
- Operative and discharge reports if previously treated
- Pathology report and BRAF V600E result if applicable
- Radiotherapy summary, dose and plan if previously irradiated
- Hydrocephalus or shunt history
- Current neurological, metabolic and hypothalamic symptoms
- Requested service: second opinion, first surgery, recurrence surgery, radiotherapy, re-irradiation or molecular review
Official sources
Last source-reviewed 2026-09-05. Cost procedures and published service fees can change, so confirm current terms directly with the provider before transferring money or booking travel.
- Skull Base Center – craniopharyngioma — Heidelberg University Hospital ↗
- International treatment inquiry and cost calculation workflow — Heidelberg University Hospital ↗
- International patients — Charité – Universitätsmedizin Berlin ↗
- 2025 craniopharyngioma consensus statement — Annales d'Endocrinologie ↗
- 2025 targeted therapy review — World Neurosurgery ↗